Previous 10 | Next 10 |
Theravance Biopharma (NASDAQ: TBPH ) has priced its public offering of 5.5M ordinary shares at $27.00 per share, for expected gross proceeds of ~$148.5M. More news on: Theravance Biopharma, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
DUBLIN , Feb. 11, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the ...
DUBLIN , Feb. 10, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today that...
Drug developer Theravance Biopharma (NASDAQ: TBPH) is not your typical biotech company. It emerged in 2014 from a spinoff of the R&D branch of its parent company, now called Innoviva (NASDAQ: INVA) . Shareholders in Innoviva received a dividend of Theravance Biopharma stock. The R&am...
DUBLIN , Jan. 7, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast its presentation at the 38 th Annual J.P. Morgan Healt...
Theravance Biopharma (NASDAQ: TBPH ) enters a global license pact with Pfizer (NYSE: PFE ) for Theravance's preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized. More news on: Theravance Biopharma, Inc., Pfizer Inc., H...
DUBLIN and NEW YORK , Dec. 23, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE: PFE) ("Pfizer") today announced that the companies have entered into a global license ...
DUBLIN , Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 allergen challenge study of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JAK) in...
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Seth Klarman’s Baupost Group Holdings...
Theravance Biopharma, Inc. (TBPH) Q3 2019 Earnings Conference Call November 5, 2019 17:00 ET Corporate Participants Jessica Stitt - Vice President, Finance and Investor Relations Rick Winningham - Chief Executive Officer Brett Haumann - Chief Medical Officer Frank Pasqualone - ...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 PR Newswire DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update af...